BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 5:04:00 PM | Browse: 996 | Download: 665
Publication Name World Journal of Gastroenterology
Manuscript ID 5848
Country/Territory United States
Received
2013-09-28 15:44
Peer-Review Started
2013-09-29 12:22
To Make the First Decision
2013-10-22 16:35
Return for Revision
2013-10-23 11:00
Revised
2013-10-25 05:29
Second Decision
2013-11-13 12:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-11-13 15:17
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-01-20 09:55
Publish the Manuscript Online
2014-03-12 14:46
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Hepatic inflammation and progressive liver fibrosis in chronic liver disease
Manuscript Source Invited Manuscript
All Author List Albert J Czaja
Funding Agency and Grant Number
Corresponding Author Albert J Czaja, MD, Professor Emeritus of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 1st St SW, Rochester, MN 55905, United States. czaja.albert@mayo.edu
Key Words Inflammation; Fibrosis; Cirrhosis; Treatment; Anti-oxidants; Angiotensin receptors; Investigational drugs
Core Tip The prevention of hepatic fibrosis and the reversal of cirrhosis are now achievable objectives in the management of chronic liver disease. Conventional immunosuppressive, anti-inflammatory, and anti-viral therapies can accomplish these outcomes by reducing liver damage, suppressing hepatic inflammation, and eliminating etiological agents, but they do so inconsistently and indirectly. The continuing clarification of pro-fibrotic mechanisms affords opportunities to design site-specific, anti-fibrotic interventions. Anti-oxidants and angiotensin inhibitors have shown promise as adjunctive anti-fibrotic agents in preliminary human studies, and they exemplify a genre of interventions that are likely to influence future management strategies.
Publish Date 2014-03-12 14:46
Citation Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014; 20(10): 2515-2532
URL http://www.wjgnet.com/1007-9327/full/v20/i10/2515.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i10.2515
Full Article (PDF) WJG-20-2515.pdf
Full Article (Word) WJG-20-2515.doc
Manuscript File 5848-Review.doc
Answering Reviewers 5848-Answering reviewers.pdf
Copyright License Agreement 5848-Copyright assignment.pdf
Peer-review Report 5848-Peer reviews.pdf
Scientific Editor Work List 5848-Scientific editor work list.doc